We found that among our late-stage tumor cohort, 40 patients met the criteria of having negative/low tumor co-expression of MRP2/CXCR4/PD-L1 which, according to our results, translates into an inferior prognosis (HR = 2.62, median OS time of only six months). This evidence concerns the gene CXCR4 and neoplasm.